Teva Enrolls Patients for Second Phase III Trial of Laquinimod

Patients with relapsing-remitting multiple sclerosis are being enrolled in Teva Pharmaceutical and Active Biotech’s second global Phase III clinical trial of laquinimod.

BRAVO, a randomized, double-blind, parallel-group, placebo-controlled study, will compare the safety and efficacy of laquinimod with placebo, as well as the risk-benefit data for the drug compared with Avonex, an injectable treatment. The enrollment goal is roughly 1,200 patients, Teva said.

The once-daily, immunomodulatory compound can be taken orally whereas other treatments are administered through injection or infusion. Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical in June 2004.